Psych Congress NetworkFDA Grants DT120 Second Breakthrough Designation, Now for MDD

📋 Regulatory Action / Label Change

The FDA has granted Breakthrough Therapy designation to DT120, an investigational oral disintegrating tablet formulation of lysergide, for the treatment of major depressive disorder (MDD). The designation was supported by results from the phase 3 Emerge trial, a randomized, double-blind, placebo-controlled study involving 149 patients with confirmed MDD. According to company-reported topline data, a single 100-µg dose produced significant improvements in depressive symptoms through 12 weeks. DT120 previously received Breakthrough Therapy designation for generalized anxiety disorder, but regulatory designation does not establish efficacy or constitute FDA approval.

Clinical Considerations

• The phase 3 Emerge study randomized 149 patients across 20 US sites to receive a single 100-µg DT120 dose or placebo.
• Company-reported data demonstrated a placebo-adjusted MADRS improvement of 8.1 points at Week 6 and 7.3 points at Week 12 (both p < .0001).
• Reported antidepressant effects were described as rapid in onset and sustained through 12 weeks following a single administration.
• Adverse events were reportedly mild to moderate and transient, with low discontinuation rates and no observed increase in suicidal ideation or behavior.
• The ongoing phase 3 Ascend trial incorporates a low-dose comparator arm intended to improve treatment masking and reduce functional unblinding.
• Findings currently derive from company-reported topline analyses; peer-reviewed publication and regulatory review remain important next steps.

Practice Applications

• Recognize that Breakthrough Therapy designation reflects regulatory recognition of potential clinical benefit rather than treatment approval.
• Interpret current findings within the context of company-reported phase 3 data that have not yet resulted in FDA authorization.
• Monitor forthcoming peer-reviewed publications and detailed safety analyses from the Emerge and Ascend programs.
• Consider DT120 as part of the broader emerging psychedelic-treatment landscape for depression and anxiety disorders.
• Discuss investigational psychedelic therapies separately from currently approved treatment options and established standards of care.